Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_assertion type Assertion NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_head.
- NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_assertion description "[Moreover, the PI3K-mTOR inhibitor NVP-BEZ235, which is in clinical use, synergized with the lysosomotropic inhibitor of autophagy, chloroquine, another agent in clinical use, to induce apoptosis in glioma xenografts in vivo, providing a therapeutic approach potentially translatable to humans.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_provenance.
- NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_assertion evidence source_evidence_literature NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_provenance.
- NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_assertion SIO_000772 21062993 NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_provenance.
- NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_assertion wasDerivedFrom befree-2016 NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_provenance.
- NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_assertion wasGeneratedBy ECO_0000203 NP851495.RAADsLyew4mhbFVcfQGoBTYEhrHH1lWBBJI2_d-xhfxEg130_provenance.